Tumour Immunotherapy and Applications of Immunological Products: A Review of Literature

Overview

Journal J Immunol Res

Publisher Wiley

Specialty Allergy & Immunology

Date 2024 Nov 1

PMID 39483536

Authors

Angus Nnamdi Oli

Samson Adedeji Adejumo

Adekunle Babajide Rowaiye

Joyce Oloaigbe Ogidigo

Jarrad Hampton-Marcell

Gordon C Ibeanu

Affiliations

Soon will be listed here.

Abstract

Malignant tumors, characterized by uncontrolled cell proliferation, are a leading global health challenge, responsible for over 9.7 million deaths in 2022, with new cases expected to rise to 35 million annually by 2050. Immunotherapy is preferred to other cancer therapies, offering precise targeting of malignant cells while simultaneously strengthening the immune system's complex responses. Advances in this novel field of science have been closely linked to a deeper knowledge of tumor biology, particularly the intricate interplay between tumor cells, the immune system, and the tumor microenvironment (TME), which are central to cancer progression and immune evasion. This review offers a comprehensive analysis of the molecular mechanisms that govern these interactions, emphasizing their critical role in the development of effective immunotherapeutic products. We critically evaluate the current immunotherapy approaches, including cancer vaccines, adoptive T cell therapies, and cytokine-based treatments, highlighting their efficacy and safety. We also explore the latest advancements in combination therapies, which synergistically integrate multiple immunotherapeutic strategies to overcome resistance and enhance therapeutic outcomes. This review offers key insights into the future of cancer immunotherapy with a focus on advancing more effective and personalized treatment strategies.

References

Levental K, Yu H, Kass L, Lakins J, Egeblad M, Erler J . Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell. 2009; 139(5):891-906. PMC: 2788004. DOI: 10.1016/j.cell.2009.10.027. View

Sharma P, Hu-Lieskovan S, Wargo J, Ribas A . Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell. 2017; 168(4):707-723. PMC: 5391692. DOI: 10.1016/j.cell.2017.01.017. View

Ohishi T, Kato Y, Kaneko M, Ohba S, Inoue H, Harakawa A . Anti-Metastatic Activity of an Anti-EGFR Monoclonal Antibody against Metastatic Colorectal Cancer with p.G13D Mutation. Int J Mol Sci. 2020; 21(17). PMC: 7504481. DOI: 10.3390/ijms21176037. View

Maude S, Laetsch T, Buechner J, Rives S, Boyer M, Bittencourt H . Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018; 378(5):439-448. PMC: 5996391. DOI: 10.1056/NEJMoa1709866. View

Yang D, Liu J, Qian H, Zhuang Q . Cancer-associated fibroblasts: from basic science to anticancer therapy. Exp Mol Med. 2023; 55(7):1322-1332. PMC: 10394065. DOI: 10.1038/s12276-023-01013-0. View

Wculek S, Cueto F, Mujal A, Melero I, Krummel M, Sancho D . Dendritic cells in cancer immunology and immunotherapy. Nat Rev Immunol. 2019; 20(1):7-24. DOI: 10.1038/s41577-019-0210-z. View

Zahavi D, Weiner L . Monoclonal Antibodies in Cancer Therapy. Antibodies (Basel). 2020; 9(3). PMC: 7551545. DOI: 10.3390/antib9030034. View

Qian S, Wei Z, Yang W, Huang J, Yang Y, Wang J . The role of BCL-2 family proteins in regulating apoptosis and cancer therapy. Front Oncol. 2022; 12:985363. PMC: 9597512. DOI: 10.3389/fonc.2022.985363. View

Abbott M, Ustoyev Y . Cancer and the Immune System: The History and Background of Immunotherapy. Semin Oncol Nurs. 2019; 35(5):150923. DOI: 10.1016/j.soncn.2019.08.002. View

10.

Berraondo P, Sanmamed M, Ochoa M, Etxeberria I, Aznar M, Perez-Gracia J . Cytokines in clinical cancer immunotherapy. Br J Cancer. 2018; 120(1):6-15. PMC: 6325155. DOI: 10.1038/s41416-018-0328-y. View

11.

Kuderer N, Desai A, Lustberg M, Lyman G . Mitigating acute chemotherapy-associated adverse events in patients with cancer. Nat Rev Clin Oncol. 2022; 19(11):681-697. DOI: 10.1038/s41571-022-00685-3. View

12.

Andtbacka R, Kaufman H, Collichio F, Amatruda T, Senzer N, Chesney J . Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. J Clin Oncol. 2015; 33(25):2780-8. DOI: 10.1200/JCO.2014.58.3377. View

13.

Schmid P, Adams S, Rugo H, Schneeweiss A, Barrios C, Iwata H . Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med. 2018; 379(22):2108-2121. DOI: 10.1056/NEJMoa1809615. View

14.

Topalian S, Taube J, Anders R, Pardoll D . Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer. 2016; 16(5):275-87. PMC: 5381938. DOI: 10.1038/nrc.2016.36. View

15.

Potente M, Gerhardt H, Carmeliet P . Basic and therapeutic aspects of angiogenesis. Cell. 2011; 146(6):873-87. DOI: 10.1016/j.cell.2011.08.039. View

16.

Shah K, Al-Haidari A, Sun J, Kazi J . T cell receptor (TCR) signaling in health and disease. Signal Transduct Target Ther. 2021; 6(1):412. PMC: 8666445. DOI: 10.1038/s41392-021-00823-w. View

17.

Li Y, Zhao L, Li X . Hypoxia and the Tumor Microenvironment. Technol Cancer Res Treat. 2021; 20:15330338211036304. PMC: 8358492. DOI: 10.1177/15330338211036304. View

18.

Duan Z, Ho M . T-Cell Receptor Mimic Antibodies for Cancer Immunotherapy. Mol Cancer Ther. 2021; 20(9):1533-1541. PMC: 8419142. DOI: 10.1158/1535-7163.MCT-21-0115. View

19.

Hosseini S, Khalili S, Baradaran B, Bidar N, Shahbazi M, Mosafer J . Bispecific monoclonal antibodies for targeted immunotherapy of solid tumors: Recent advances and clinical trials. Int J Biol Macromol. 2020; 167:1030-1047. DOI: 10.1016/j.ijbiomac.2020.11.058. View

20.

Hinrichs C, Restifo N . Reassessing target antigens for adoptive T-cell therapy. Nat Biotechnol. 2013; 31(11):999-1008. PMC: 4280065. DOI: 10.1038/nbt.2725. View